Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in active psoriatic arthritis
NCT02969525Phase 2Completed
- Sponsor
- UCB
- Start
- Oct 2016
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in psoriatic arthritis (PsA) (5 arms), sponsored by UCB. Primary endpoint: American College of Rheumatology 50% Improvement at 12 weeks. Started Oct 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02969525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969525.